Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop ...

Life sciences organizations face challenges spanning culture, leadership, infrastructure, and skills to implement FAIR data ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

As anxiety disorders become more common and stress from the diverse impacts of the COVID-19 pandemic threaten the mental/emotional well-being of Americans everywhere, it is clear that the current ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...

Implementing AI in drug discovery offers significant potential for reducing operating costs, though the extent varies widely. A Deloitte report suggests AI could cut drug development costs by up to 70 ...

In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...

During my stint (five years and some change) as a senior manager in PwC’s Health Research Institute, I had the opportunity to work on the pharmaceutical and life sciences sections of several Medical ...

THERE ARE THREE ESSENTIAL COMPONENTS TO A WORKING VALUE-BASED CONTRACT: it must: 1) focus on real and meaningful patient outcomes to which payers and manufacturers can agree; 2) provide the payer with ...